F-10POS: Oncolytics Biotech Deregisters Unsold Securities
Post-Effective Amendment to Registration Statement
Oncolytics Biotech Inc. has filed a post-effective amendment to deregister unsold securities from multiple previous registration statements.
Summary
- Oncolytics Biotech Inc. is filing a post-effective amendment to Form F-10 registration statements.
- The purpose of this filing is to withdraw and deregister the unsold portion of securities that were previously registered.
- This action applies to ten different registration statements filed between February 5, 2007, and July 25, 2024.
- The securities involved include units, common shares, subscription receipts, warrants, and debt securities.
- The amendment is set to become effective on April 16, 2026, at 4:30 p.m. Eastern time.
Sentiment
Score: 3
Explanation: StockSavvy.ai views this as a neutral filing, as it is an administrative action to deregister unsold securities from past offerings and does not reflect current operational or financial performance.
Future Outlook
The filing indicates that the post-effective amendment to deregister unsold securities will become effective on April 16, 2026.
Industry Context
StockSavvy.ai notes that this filing is a procedural administrative action to clean up past registration statements where securities were not fully sold, which is common for companies that have conducted multiple offerings over time.
Stakeholder Impact
- Shareholders: No immediate impact as this relates to previously registered but unsold securities. It simplifies past filings.
Next Steps
- The post-effective amendment will become effective on April 16, 2026.
- Unsold securities from previous registration statements will be deregistered.
Key Dates
| Date | Description |
|---|---|
| February 5, 2007 | Initial filing date for Registration Statement No. 333-140460. |
| February 8, 2007 | Initial filing date for Registration Statement No. 333-140529. |
| June 6, 2008 | Initial filing date for Registration Statement No. 333-151513. |
| June 2, 2010 | Initial filing date for Registration Statement No. 333-167250. |
| June 21, 2012 | Initial filing date for Registration Statement No. 333-182260. |
| July 25, 2014 | Initial filing date for Registration Statement No. 333-197633. |
| April 25, 2018 | Initial filing date for Registration Statement No. 333-224432. |
| June 8, 2020 | Initial filing date for Registration Statement No. 333-239025. |
| June 10, 2022 | Initial filing date for Registration Statement No. 333-265510. |
| July 25, 2024 | Initial filing date for Registration Statement No. 333-281009. |
| April 8, 2026 | Date of filing of the post-effective amendment. |
| April 16, 2026 | Proposed effective date of the post-effective amendment. |
Keywords
deregistration, securities, registration statement, Oncolytics Biotech, SEC filing, Form F-10, unsold securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.